…
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bonesupport develops and commercializes medical products for bone regeneration and infection management, primarily the injectable CERAMENT calcium-sulphate bone void fillers with or without local antibiotics. Long-term growth may be supported by aging populations, rising orthopedic procedure volumes, US and international expansion, and accumulating clinical evidence and reimbursement. Investors may view the company as positioned with differentiated technology that could support surgical adoption and recurring consumable sales.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 199.02M | 172.62M | 15.75M | -64.69M | -81.84M |
| Net income | 141.80M | 133.75M | 245.02M | -68.17M | -85.53M |
| Selling general administrative | 719.26M | 98.99M | 90.31M | 73.31M | 44.12M |
| Selling and marketing expenses | - | 510.35M | 371.31M | 238.45M | 177.84M |
| Gross profit | 1084.60M | 832.25M | 540.92M | 297.71M | 189.70M |
| Reconciled depreciation | 7.74M | 7.22M | 10.07M | 9.38M | 8.28M |
| Ebit | - | 174.92M | 18.86M | -63.72M | -81.02M |
| Ebitda | 275.98M | 185.75M | 26.29M | -54.34M | -72.74M |
| Depreciation and amortization | - | 10.83M | 7.43M | 9.38M | 8.28M |
| Operating income | 275.98M | 166.15M | 13.93M | -64.53M | -80.67M |
| Other operating expenses | 895.74M | 732.58M | 577.15M | 396.42M | 297.46M |
| Interest expense | 32.08M | 2.29M | 3.12M | 0.97M | 1.17M |
| Tax provision | 57.36M | 38.87M | -229.27M | 3.47M | 3.69M |
| Interest income | 7.27M | 8.77M | 4.93M | 0.81M | 0.00M |
| Net interest income | -32.16M | 6.48M | 1.82M | -0.16M | -1.17M |
| Income tax expense | 57.22M | 38.87M | -229.27M | 3.47M | 3.69M |
| Total revenue | 1171.71M | 898.73M | 591.08M | 328.82M | 212.88M |
| Total operating expenses | 808.62M | 666.10M | 526.99M | 365.31M | 274.28M |
| Cost of revenue | 87.11M | 66.48M | 50.16M | 31.11M | 23.18M |
| Total other income expense net | -76.96M | 6.48M | 1.82M | -0.16M | -1.17M |
| Net income from continuing ops | 142.15M | 133.75M | 245.02M | -68.17M | -85.53M |
| Net income applicable to common shares | - | - | - | -68.17M | -85.53M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1033.54M | 879.69M | 688.82M | 371.82M | 343.92M |
| Intangible assets | 14.91M | 14.54M | 4.04M | 8.38M | 8.37M |
| Other current assets | 57.98M | 20.75M | 35.72M | 0.00M | -0.00M |
| Total liab | 168.46M | 152.23M | 143.64M | 102.89M | 78.22M |
| Total stockholder equity | 865.08M | 727.46M | 545.18M | 268.93M | 265.70M |
| Deferred long term liab | - | - | - | 6.31M | 5.97M |
| Other current liab | 140.03M | 106.70M | 99.61M | 61.52M | 37.71M |
| Common stock | 41.62M | 41.73M | 41.37M | 41.36M | 40.91M |
| Capital stock | 41.73M | 41.73M | 41.37M | 41.36M | 40.91M |
| Retained earnings | -726.78M | -886.77M | -1061.19M | -1344.68M | -1344.49M |
| Other liab | - | - | - | 0.34M | 0.36M |
| Other assets | - | - | - | 6.31M | 5.97M |
| Cash | 377.04M | 227.00M | 166.93M | 201.28M | 206.46M |
| Total current liabilities | 163.91M | 144.19M | 130.06M | 90.20M | 61.70M |
| Current deferred revenue | - | - | 6.52M | 55.18M | 32.09M |
| Net debt | -365.36M | -212.41M | -149.44M | -183.83M | -185.04M |
| Short term debt | 7.48M | 6.93M | 4.26M | 5.10M | 5.27M |
| Short long term debt total | 11.68M | 14.59M | 17.48M | 17.45M | 21.42M |
| Other stockholder equity | 1562.00M | 1572.51M | 1563.86M | 1572.24M | 1569.29M |
| Property plant equipment | - | - | - | 24.62M | 27.08M |
| Total current assets | 794.66M | 622.60M | 402.94M | 338.81M | 308.48M |
| Net tangible assets | - | - | - | 266.85M | 263.31M |
| Short term investments | - | - | 0.42M | - | - |
| Net receivables | 215.01M | 240.73M | 116.56M | 81.22M | 50.25M |
| Inventory | 144.63M | 134.11M | 83.30M | 56.31M | 51.76M |
| Accounts payable | 16.40M | 17.84M | 19.66M | 23.57M | 18.72M |
| Accumulated other comprehensive income | -11.76M | 6.58M | 1.13M | - | - |
| Non currrent assets other | 0.00M | 0.43M | 257.84M | 0.00M | -0.00M |
| Non current assets total | 238.88M | 257.10M | 285.88M | 33.01M | 35.44M |
| Capital lease obligations | 11.68M | 14.59M | 17.48M | 17.45M | 21.42M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.69M | -6.26M | -6.06M | -3.28M | -3.42M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -5.87M | -6.26M | -6.06M | -3.28M | -3.42M |
| Net borrowings | - | - | - | -8.13M | -5.51M |
| Total cash from financing activities | -57.89M | -4.75M | -6.70M | 42.78M | -61.56M |
| Change to operating activities | - | - | - | 24.06M | 0.96M |
| Net income | 141.80M | 166.15M | 245.02M | -64.53M | -80.67M |
| Change in cash | 188.69M | 59.65M | -33.93M | -5.18M | -147.27M |
| Begin period cash flow | 188.35M | 167.35M | 201.28M | 206.46M | 353.74M |
| End period cash flow | 377.04M | 227.00M | 167.35M | 201.28M | 206.46M |
| Total cash from operating activities | 220.75M | 65.70M | -18.26M | -46.98M | -83.42M |
| Issuance of capital stock | 0.00M | 2.42M | 0.03M | 50.91M | 6.28M |
| Depreciation | 7.74M | 7.22M | 7.43M | 9.38M | 8.28M |
| Other cashflows from investing activities | - | -4.31M | -5.24M | - | - |
| Change to inventory | -60.78M | -22.00M | -37.43M | 7.08M | -0.12M |
| Change to account receivables | - | -95.39M | -77.62M | -25.98M | -5.42M |
| Sale purchase of stock | -16.25M | 0.00M | - | - | -62.33M |
| Other cashflows from financing activities | -57.83M | -0.20M | -0.16M | -8.13M | -5.51M |
| Change to netincome | - | - | - | 6.64M | -1.59M |
| Capital expenditures | 2.56M | 5.84M | 6.06M | 3.28M | 3.42M |
| Change in working capital | -68.83M | -92.56M | -97.69M | 5.16M | -4.58M |
| Stock based compensation | 32.31M | 15.89M | 39.92M | 17.89M | 7.37M |
| Other non cash items | 147.78M | -30.99M | -212.93M | -14.88M | -13.81M |
| Free cash flow | 218.19M | 59.86M | -24.32M | -50.26M | -86.84M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BOEUF Bonesupport Holding AB (publ) |
- -% |
31.86 | 74.03 | - | 12.30 | 16.30 | 10.93 | 48.13 |
| ISRG Intuitive Surgical Inc |
-8.32 2.04% |
398.92 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.84 1.45% |
192.96 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.82 1.88% |
95.04 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.10 0.05% |
212.78 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
| Name | Title | Year Born |
|---|---|---|
| Mr. Emil Billbäck | Chief Exec. Officer | 1970 |
| Prof. Lars A. Lidgren M.D., Ph.D. | Founder & Director | 1943 |
| Mr. Håkan Johansson | Chief Financial Officer | 1963 |
| Ms. Ann-Marie Thor | Acting Exec. VP of Global Marketing | NA |
| Ms. Helena L. Brandt | Head of HR | 1965 |
| Dr. Michael Diefenbeck M.D., Ph.D. | Exec. VP of Medical & Clinical Affairs and Chief Medical Officer | 1974 |
| Dr. Jerry Chang | Exec. VP of R&D, Regulatory and Clinical | 1959 |
| Mr. Fergus MacLeod | GM & Exec. VP of Commercial Operations of EUROW | 1970 |
| Ms. Kristina Ingvar | Exec. VP of Quality Management & Regulatory Affairs | 1972 |
| Mr. Michael Roth | GM & Exec. VP of Commercial Operations of North America | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.